Status:

COMPLETED

Plasmatic Concentrations of Propofol and Remifentanil in Obese and Non Obese Patients.

Lead Sponsor:

University Hospital, Clermont-Ferrand

Conditions:

General Anesthesia

Obesity

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This prospective monocentric phamacokinetics study aims to compare plasmatic concentrations of Propofol and Remifentanil required to target a specific range of monitored anesthesia and analgesia durin...

Detailed Description

Remifentanil and Propofol are administered intravenously as an opioid pain reliever and hypnotic pain reliever during anesthesia. Their advantages are numerous: short half-life allowing anesthesia and...

Eligibility Criteria

Inclusion

  • Obese patients group:
  • Age ≥ 18 years old
  • Severe and morbidly obese patients (35kg / m2≤IMC \<55kg / m2).
  • Patients undergoing general anesthesia for laparoscopic susmesocolic surgery (bariatric surgery or cholecystectomy).
  • Patients who have given their consent in the manner described by the public health law of August 9, 2004.
  • Patients benefiting from a Social Security scheme.
  • Group of non-obese patients:
  • Age ≥ 18 years old
  • Patients with normal weight or slightly overweight (19 \<BMI \<30).
  • Patients receiving general anesthesia for laparoscopic susmesocolic surgery (cholecystectomy).
  • Patients who have given their consent in the manner described by the public health law of August 9, 2004.
  • Patients benefiting from a Social Security scheme.

Exclusion

  • Patient refusal
  • Age \<18 years old
  • Protected adults and vulnerable persons
  • Pace maker
  • General anesthesia in the 24 hours preceding this surgery
  • Proven or suspected dysautonomia
  • Premedication by gabapentin Neurontin °
  • Locoregional peri-medullary analgesia technique used concomitantly during the pre- and intraoperative period.
  • Unbalanced dysrhythmic heart disease (AC / FA; extrasystoles; non-sinus rhythm)
  • Pregnant or breastfeeding woman
  • Intubation impossible planned
  • Hypersensitivity to the products used
  • Allergy to peanut or soy

Key Trial Info

Start Date :

December 20 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 25 2021

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04492813

Start Date

December 20 2018

End Date

May 25 2021

Last Update

August 25 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Service d'Anesthésie-Réanimation, Pôle Médecine Périopératoire - Hôpital Estaing, CHU de Clermont-Ferrand

Clermont-Ferrand, Puy De Dôme, France, 63000